Chronic Airways Assessment Test (CAAT)
Chronic Airways Assessment Test: A unified tool for assessing chronic airway diseases
CAAT can now be used for assessing respiratory health status in people with asthma, not just COPD
A simple and standardized health status measure
A standardized, easy to administer, health status measure for use across obstructive lung diseases.
Structure and components of the CAAT
8-items assessing aspects of disease relevant to patients.
Development and validation
The COPD assessment test (CAT) and the Chronic Airways Test (CAAT) were developed by an interdisciplinary group of international experts with support from GSK.
CAT and CAAT activities are monitored by a supervisory council that includes independent experts, one of which is chair of the council.
CAT, COPD Assessment Test, CAAT, Chronic Airways Assessment Test and the CAT logo are trademarks of the GSK group of companies.
Implementation and resources
Scan the QR code for the CAAT User Guide.
Documents for download
Read more details at
Fecha de publicación
September 2025
Categorías asociadas al artículo
Noticias relacionadas
A GOLD Science Committee Report on Universal Longitudinal Spirometry: A New Paradigm
Universal longitudinal spirometry from childhood: GOLD proposes monitoring lung function trajectories to preserve lifelong respiratory health.
Bronchial and Systemic Relationships of Haemophilus in Chronic Obstructive Pulmonary Disease
Haemophilus in COPD: a study of bronchial microbiome composition, exacerbation patterns, hospital admissions and relationships with blood interleukin-8 levels.
A Proposed Consensus Definition of Severe
Explore a proposed consensus definition of severe COPD and a structured work-up addressing symptoms, functional impairment, quality of life and clinical characteristics.
Awareness of chronic obstructive pulmonary disease in the adult population of seven African cities: a comparative analysis with asthma and HIV from the RACE Africa study
COPD awareness in Africa is low: the RACE Africa survey in seven cities finds limited knowledge of risk factors and symptoms compared with asthma and HIV.
Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD
AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Imagen obtenida de la presentación